Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Hadas Reuveni, Lana Kupershmidt, Emmanuelle Merquiol, Galia Blum, Ohad Ronen, Izhak Haviv
Title NT219, a novel dual inhibitor of STAT3 and IRS1/2, demonstrates anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models
URL https://cancerres.aacrjournals.org/content/80/16_Supplement/5639
Abstract Text Background: Pembrolizumab with chemotherapy is approved as first line therapy for recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Patients refractory to this regimen are often treated with cetuximab. Historically, cetuximab monotherapy resulted in a median response rate of ~13% and an overall survival of ~6 months in patients with platinum-resistant R/M HNSCC. Better therapies for this population are therefore highly warranted. Insulin Receptor Substrate 1 and 2 (IRS1/2) and STAT3 are major signaling junctions regulated by various oncogenes and altered during epithelial-to-mesenchymal transition and drug resistance. Feedback activation of STAT3 and IGF1R/IRS plays a prominent role in mediating drug resistance to EGFR blockers. STAT3 has also been demonstrated to play an active role in tumor's immune evasion. NT219 is a novel small molecule dual inhibitor of IRS1/2 and STAT3. The purpose of this study was to evaluate NT219 anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models. Methods: Mice were inoculated with biopsies from naïve or platinum and anti-PD1 treated head and neck cancer patients. PBMCs or CD34+ cells from the same patient from whom the biopsy was obtained, were injected to allow immune system involvement in the anti-tumoral effect. Immunoblotting, immunohistochemistry and FACS analyses were used to assess the pharmacodynamic effect of NT219 and to explore mechanism of action. Results: HNSCC cells treated with NT219 demonstrated elimination of IRS1/2 and dephosphorylation of STAT3. A short exposure to NT219 induced prolonged inhibition of both IRS and STAT3 and resulted in cancer cell apoptosis. In PDX models of the head and neck cancer, NT219 induced tumor growth inhibition and regression as a monotherapy (3/6), and in combination with cetuximab or pembrolizumab (5/6), respectively. Of particular interest was a model, which originated from a biopsy of R/M HNSCC patient previously treated and progressed on radiation, various chemotherapies, and pembrolizumab, where autologous PBMC's were injected. Administration of NT219 as a monotherapy resulted in tumor growth inhibition (TGI) of 69% (p-value=0.017). In combination with cetuximab, NT219 induced regression of all tumors. While cetuximab alone demonstrated modest TGI (17%), the addition of NT219 showed synergistic effect and complete TGI (p-value=0.001). Similar results were obtained in a repeated experiment where CD34+ cells were used. Conclusion: NT219 induced tumor regression of R/M HNSCC and sensitized resistant tumors to cetuximab and pembrolizumab. The unique mechanism of NT219, targeting two central mechanisms involved in cancer drug resistance, supports further clinical development of NT219 which may present an attractive 2nd and 3rd line therapy.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
NT219 NT219 0 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
NT219 NT-219|NT 219 STAT3 Inhibitor 26 NT219 is a small molecule that inhibits both Stat3 and Irs1/2, resulting in decreased Stat3 phosphorylation and increased degradation of Irs1/2, and potentially leading to tumor growth inhibition (Cancer Res 2020;80(16 Suppl):Abstract nr 5639).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References